证券代码：872925 证券简称：锦好医疗 公告编号：2023-039 惠州市锦好医疗科技股份有限公司 独立董事关于第二届董事会第二十五次会议有关事项的独立意见 惠州市锦好医疗科技股份有限公司（以下简称"公司"）于2023 年 4 月 25 日召开了第二届董事会第二十五次会议。根据《公司章程》、《独立董事工作制度》等 相关规章制度的有关规定，作为公司的独立董事，我们本着高度负责的态度，在审 慎查验的基础上，对公司第二届董事会第二十五次会议中相关事项发表如下独立意 见： 一、《关于在建工程转固、转投资性房地产并采用成本价值模式计量的议 案》的独立意见 经查阅锦好智慧医疗产业园的相关资料，该项目已达到预定可使用状态，拟 进行转固、转投资性房地产并采用成本价值进行后续计量，能准确反映公司资产 的价值，符合企业会计准则的相关规定，不存在变更会计政策，不存在损害公司 及股东，特别是中小股东利益的情形。我们同意公司将在建工程转固、转投资性 房地产并采用成本价值进行后续计量。 独立董事：袁英红 李忠轩 2023 年 4 月 27 日 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2023-038 惠州市锦好医疗科技股份有限公司 关于在建工程转固、转投资性房地产并采用 成本价值模式计量的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整、没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 一、关于在建工程转固、转投资性房地产的基本情况 惠州市锦好医疗科技股份有限公司（以下简称"公司"）募投项目"智慧医疗产 品生产基地建设项目及智能助听器设计研究中心项目"（以下简称"锦好智慧医疗产 业园"）于 2023 年 3 月 22 日通过竣工及消防联合验收，截至 2023 年 4 月份已达到 预定可使用状态，预计将产生一定的经济利益流入，相关成本及收益能够可靠计量， 具备暂估转固、转投资性房地产的条件。根据《企业会计准则第 3 号——投资性房地 产》《企业会计准则第 4 号—固定资产》的相关规定，为了真实反映公司的财务状况 和资产价值，公司拟将锦好智慧医疗产业园从"在建工程"结转至"固定资产""投 资性房地产"科目核算。具体情况如下： | 项目名称 | | 账面价值（万元） | 建筑面积 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2023-036 惠州市锦好医疗科技股份有限公司 第二届监事会第十八次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 4 月 25 日 2.会议召开地点：公司会议室 3.会议召开方式：现场会议 4.发出监事会会议通知的时间和方式：2023 年 4 月 21 日以书面方式发出 5.会议主持人：黄小华先生 6.召开情况合法、合规、合章程性说明： 二、议案审议情况 （一）审议通过《关于公司 2023 年第一季度报告的议案》 1.议案内容： 根据相关法规及公司章程的规定，公司编制了《2023 年第一季度报告》，具 体内容详见公司同日在北京证券交易所指定披露平台（www.bse.cn）披露的《2023 年第一季度报告》（公告编号 2023-040）。 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 票。 3.回避表决情况 本议案不涉及关联事项，无需回避表决。 本次 ...

Financial Performance - Operating revenue for the first quarter of 2023 reached CNY 59.37 million, representing a year-on-year growth of 57.49% from CNY 37.69 million[10] - Net profit attributable to shareholders for the first quarter of 2023 was CNY 11.22 million, a significant increase of 100.74% compared to CNY 5.59 million in the same period last year[10] - The gross profit margin improved due to an increase in the sales proportion of hearing aids, leading to a 132.12% increase in operating profit to CNY 13.25 million[17] - Total revenue for Q1 2023 reached ¥59,366,785.38, a significant increase from ¥37,694,584.15 in Q1 2022, representing a growth of approximately 57.5%[49] - The net profit for Q1 2023 reached 12,005,443.63 yuan, compared to 5,365,879.18 yuan in Q1 2022, indicating a year-over-year increase of about 123.5%[51] - The total profit for Q1 2023 was 13,258,282.80 yuan, up from 5,948,961.20 yuan in Q1 2022, reflecting an increase of approximately 122.5%[51] Cash Flow - The company's cash flow from operating activities for the first quarter was CNY 6.08 million, down 16.38% from CNY 7.27 million in the previous year[10] - Cash inflow from operating activities for Q1 2023 was CNY 54,310,200.09, an increase of 17.5% compared to CNY 46,223,409.90 in Q1 2022[56] - Net cash flow from operating activities for Q1 2023 was CNY 6,081,517.69, a decrease of 16.4% from CNY 7,272,807.75 in Q1 2022[56] - Cash inflow from investment activities in Q1 2023 was CNY 105,611,289.58, up 77% from CNY 59,722,149.17 in Q1 2022[57] - Net cash flow from investment activities for Q1 2023 was CNY 13,562,348.45, a significant recovery from a negative CNY 34,038,114.12 in Q1 2022[57] Assets and Liabilities - Total assets as of March 31, 2023, amounted to CNY 449.90 million, an increase of 7.72% compared to CNY 417.66 million at the end of 2022[10] - The company's asset-liability ratio (consolidated) increased to 17.34% from 12.67% year-on-year, indicating a rise in leverage[10] - Total liabilities rose to ¥78,011,395.98 in Q1 2023, up from ¥52,905,039.28 in Q4 2022, indicating an increase of approximately 47.8%[43] - Current liabilities totaled ¥72,255,980.83 as of March 31, 2023, compared to ¥47,506,643.47 at the end of 2022, marking a rise of around 51.9%[43] - Non-current assets amounted to ¥259,504,061.89 as of March 31, 2023, up from ¥230,673,684.25 at the end of 2022, showing an increase of about 12.5%[43] Shareholder Information - The total number of unrestricted shares is 27,667,955, representing 56.15% of the total share capital[23] - The total number of restricted shares is 21,607,045, representing 43.85% of the total share capital[23] - The largest shareholder, Wang Min, holds 12,703,057 shares, accounting for 25.78% of the total shares[26] - The second-largest shareholder, Wang Fang, holds 9,526,818 shares, accounting for 19.33% of the total shares[26] - The company has a total share capital of 49,275,000 shares[23] Research and Development - Research and development expenses for the quarter were CNY 5.09 million, reflecting a 67.36% increase, indicating a continued commitment to R&D investment[16] - Research and development expenses for Q1 2023 amounted to 5,091,791.65 yuan, up from 3,042,481.56 yuan in Q1 2022, reflecting a growth of approximately 67.1%[50] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[49] - The company is actively pursuing strategies for market expansion and new product development as part of its growth initiatives[36] Legal and Compliance - The company has not reported any significant legal disputes or external guarantees during the reporting period[29] - The company has committed to ensuring accurate information disclosure and has stated that there are no false records or misleading statements in its public disclosures[37]

证券代码：872925 证券简称：锦好医疗 公告编号：2023-021 惠州市锦好医疗科技股份有限公司 独立董事关于第二届董事会第二十四次会议有关事项的独立意见 惠州市锦好医疗科技股份有限公司（以下简称"公司"）于2023 年 4 月 13 日召开了第二届董事会第二十四次会议。根据《公司章程》、《独立董事工作制度》等 相关规章制度的有关规定，作为公司的独立董事，我们本着高度负责的态度，在审 慎查验的基础上，对公司第二届董事会第二十四次会议中相关事项发表如下独立意 见： 一、《关于 2022 年年度权益分派预案的议案》的独立意见 经审阅，我们认为：公司本次权益分配方案结合了公司经营情况和未来发展 需要，在维护广大投资者的合法利益的同时，也充分考虑了公司发展的流动资金 需求，有利于公司的长远发展。本次权益分配不存在损害中小投资者利益的情 形，符合公司现金分红的相关规定以及相关承诺。因此，我们同意公司 2022 年度 权益分配预案，并将该议案提交股东大会审议。 二、《关于公司 2023 年开展外汇套期保值交易的议案》的独立意见 经审阅，公司拟与银行等金融机构开展远期外汇交易业务，充分利用远期结 售汇产品的套期保值功 ...

惠州市锦好医疗科技股份有限公司《2022 年年度报告》及《2022 年年度报告 摘要》于 2023年 4月17日在北京证券交易所官方信息披露平台(http://www.bse.cn)披 露，敬请投资者注意查阅。 特此公告。 惠州市锦好医疗科技股份有限公司 董事会 2023 年 4 月 17 日 证券代码：872925 证券简称：锦好医疗 公告编号：2023-018 公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 ...

Financial Performance - In 2022, the company achieved a total revenue of CNY 195.13 million, with overseas sales accounting for 90.95% of total revenue, amounting to CNY 177.48 million[16]. - The company's operating revenue for 2022 was CNY 195,132,408.42, representing a year-on-year increase of 1.66% compared to CNY 191,946,299.04 in 2021[31]. - The net profit attributable to shareholders for 2022 was CNY 40,301,539.44, a significant increase of 76.13% from CNY 22,881,399.64 in 2021[31]. - The gross profit margin improved to 46.38% in 2022, up from 37.59% in 2021[31]. - Hearing aid revenue accounted for 91.65% of total revenue, with a year-on-year growth of 14.49% to 178.84 million yuan[46]. - The company reported a net profit growth rate of 80.39% in 2022 compared to a decline of 45.49% in 2021[35]. - The basic earnings per share for 2022 was CNY 0.82, reflecting a growth of 36.67% from CNY 0.60 in 2021[31]. - The cash flow from operating activities for 2022 was CNY 27,362,364.11, an increase of 8.47% from CNY 25,225,648.78 in 2021[34]. Research and Development - The company invested 15.61 million yuan in R&D, marking a 347.51% increase, with R&D expenses constituting 8.00% of total revenue[47]. - The company holds 140 patents and 8 copyrights, including 5 invention patents, demonstrating strong innovation capabilities[42]. - The company increased its R&D personnel from 45 to 62, with a higher proportion of employees engaged in R&D activities, rising from 14.24% to 16.40%[92]. - The company is actively developing digital hearing aids to align with market trends towards OTC, intelligent, professional, and personalized products[114]. - In 2022, the company's R&D investment reached a record high of 8.00% of total revenue, with plans to further increase R&D efforts in 2023, particularly for OTC hearing aids and HCP hearing aids[114]. Market Expansion and Sales - The company has established partnerships with major international retailers, including Walmart and Carrefour, enhancing its market presence[42]. - The company is focused on developing OTC hearing aids, which are expected to create new market opportunities and increase penetration rates[50]. - The company plans to enhance its overseas business development, particularly in the U.S. OTC market, following the easing of COVID-19 restrictions[111]. - The company plans to enhance market expansion efforts, focusing on increasing sales scale in both domestic and international markets, particularly in the Asia-Pacific, Europe, and the Middle East[113]. - The company has established three operational stores to enhance domestic sales and reduce reliance on overseas markets[120]. Corporate Governance and Compliance - The company is addressing risks related to governance and control by implementing internal control measures and enhancing its governance structure[117]. - The company has publicly disclosed that there are no false records or misleading statements in its financial reporting[143]. - The company has committed to eliminating all illegal occupation of funds and guarantees from the company and its subsidiaries[140]. - The company has established measures to address any potential economic losses resulting from breaches of competition commitments[145]. - The company will ensure effective management of raised funds, adhering to regulatory requirements and internal management systems[162]. Shareholder Commitments and Equity - The 2022 equity incentive plan granted a total of 675,000 restricted shares and 945,000 stock options to directors, senior management, and core employees[135]. - The company's share capital increased from 48.6 million shares to 49.275 million shares due to the implementation of the equity incentive plan[136]. - Major shareholders have pledged not to transfer or manage their shares for 12 months post-IPO, with a maximum of 25% of their shares allowed for transfer annually during their tenure[148]. - The company has committed to a profit distribution policy that prioritizes cash dividends, with a minimum of 10% of distributable profits to be distributed in cash annually, and a cumulative cash distribution of at least 30% of the average annual distributable profits over the last three years[169]. - The company will review its shareholder return plan at least every three years after listing on the selected tier, considering changes in circumstances or policies[171]. Investment and Asset Management - The company raised a total of RMB 210 million through a public offering, with a net amount of RMB 190.14 million after expenses[195]. - During the reporting period, the company used RMB 132.18 million of the raised funds, with a remaining balance of RMB 7.82 million as of December 31, 2022[197]. - The funds raised are allocated for the construction of a smart medical product production base and an intelligent hearing aid design research center[195]. - The total amount of raised funds invested to date is approximately ¥185.12 million, indicating a utilization rate of 95.62%[199]. - The company utilized part of the idle raised funds for cash management, with a total purchase amount of ¥12.5 million in structured deposits[199]. Social Responsibility - The company engaged in a series of successful public welfare activities in collaboration with Ruyi Tree in 2022[9]. - The company actively participated in social responsibility initiatives, providing free hearing health checks to 16,000 individuals and distributing 4,550 hearing aids in rural areas[106].

证券代码：872925 证券简称：锦好医疗 公告编号：2023-028 惠州市锦好医疗科技股份有限公司 关于召开 2022 年年度股东大会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东大会届次 本次会议为 2022 年年度股东大会。 （二）召集人 本次股东大会的召集人为董事会。 2023 年 4 月 13 日，公司召开第二届董事会第二十四次会议，审议通过《关 于提请召开 2022 年年度股东大会的议案》。 （三）会议召开的合法性、合规性 本次股东大会的召集、召开、议案审议程序等符合《公司法》、《公司章程》 及相关法律法规的有关规定。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 公司股东应选择现场投票、网络投票中的一种方式，如果同一表决权出现 重复投票表决的，以第一次投票表决结果为准。 （五）会议召开日期和时间 1、现场会议召开时间：2023 年 5 月 12 日 15:00。 2、网络投票起止时间：2023 年 5 月 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2023-029 惠州市锦好医疗科技股份有限公司 公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 一、募集资金基本情况和使用情况 （一）募集资金基本情况 根据中国证券监督管理委员会《关于核准惠州市锦好医疗科技股份有限公司向不 特定合格投资者公开发行股票的批复》（证监许可〔2021〕3113 号）文件核准，公司 向不特定合格投资者公开发行方式发行股票 1,250 万股，每股面值 1 元，发行价为每 股人民币 16.80 元，募集资金总额为人民币 210,000,000.00 元（超额配售选择权行 使后），扣除与发行有关的费用人民币 19,863,207.55 元（不含税）（超额配售选择 权行使后），实际募集资金净额为人民币 190,136,792.45 元（超额配售选择权行使 后），本次发行募集资金用途用于智慧医疗产品生产基地建设项目、智能助听器设计 研究中心项目和补充流动资金。 关于变更部分募投项目实际用途的公告 （二）募集资金的使用和存储情况 根据公 ...

中信建投证券股份有限公司 关于惠州市锦好医疗科技股份有限公司 2022 年募集资金存放与使用情况的专项核查意见 中信建投证券股份有限公司（以下简称："中信建投证券"、"保荐机构"）作 为惠州市锦好医疗科技股份有限公司（以下简称"锦好医疗"或"公司"）向不 特定合格投资者公开发行股票的保荐机构，根据《证券发行与承销管理办法》《北 京证券交易所股票上市规则（试行）》等相关规定，经审慎核查，对锦好医疗 2022 年募集资金存放与实际使用情况发表核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 根据中国证券监督管理委员会《关于核准惠州市锦好医疗科技股份有限公司 向不特定合格投资者公开发行股票的批复》（证监许可〔2021〕3113 号）文件核 准，公司向不特定合格投资者公开发行方式发行股票 1,250 万股，每股面值 1 元， 发行价为每股人民币 16.80 元，募集资金总额为人民币 210,000,000.00 元（超额 配售选择权行使后），扣除与发行有关的费用人民币 19,863,207.55 元（不含税） （超额配售选择权行使后），实际募集资金净额为人民币 190,136,792.45 ...